TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
Mac 18, 2026
2 min read
13

UniCredit CEO Andrea Orcel stated he has not ruled out improving the bank's takeover offer for Commerzbank. The comment came during a Morgan Stanley conference in London, indicating that better terms are a possibility if merger discussions yield a positive outcome.
The Italian bank launched its current bid for Commerzbank with a modest 4% premium. Orcel clarified the main purpose is to break an 18-month stalemate and restart tie-up discussions, not to gain immediate control. UniCredit's current stake in the German lender stands at just below 30 percent, including holdings through derivative contracts.
A revised offer is contingent on reaching an agreement that satisfies all stakeholders and addresses UniCredit's strategic concerns. However, Orcel described this as a 'very remote' scenario at the moment, emphasizing that the bank is not actively considering an improved bid under the current circumstances.
While the door is technically open for a higher bid, Orcel's statements suggest the current offer is a strategic maneuver to compel negotiation. Market watchers will be closely monitoring the response from Commerzbank and German regulators to see if the stalemate can be broken.
Q: Why did UniCredit launch the current bid?
A: The primary goal is to break the 18-month deadlock that followed its initial investment and to trigger new tie-up discussions.
Q: What is the premium on the current offer?
A: The offer includes a narrow 4% premium over Commerzbank's market price at the time of the announcement.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles

18 Mac 2026
FDA Approves J&J's Psoriasis Pill, Icotyde